rapid testing blood diagnostic one self check typhidot test price

Name: rapid testing blood diagnostic one self check typhidot test price
Brand: China Tianjin Recare Co., Ltd.
SKU: 2006112762

Tianjin, ChinaChina Tianjin Recare Co., Ltd.

US$0.22

1,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Type

IVD Reagent

Testing Time

15 minutes

Model NO.

typhoid antigen test

Certificate

CE, ISO

Validity

24 months

Mould

cassette

Service

OEM or ODM

Specimen

blood

Storage

2-30

MOQ

1000

Transport Package

Carton

Specification

100pcs/bottle

Trademark

Recare

Origin

Tianjin

HS Code

3822190090

Production Capacity

10000000

Company profile

Years of Export ExperienceFast Delivery100% Finished Products InspectionProduct Certification

China Tianjin Recare Co., Ltd.

Tianjin, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples CertifiedExport Year: 20 Years CertifiedNearest Port: Tianjin PortAverage Response Time: ≤3.93h

AI-Powered supplier vetting

SummaryThe supplier demonstrates OEM and ODM capabilities, sample-based customization, available SDK support, and reported new products within the past year. It has quality-assurance procedures, documented corrective-action and complaint-handling processes, and 21–30 quality-control staff. Production operates one line, with valid manufacturing contracts covering associated subcontractors and reported lead times within 15 workdays in both peak and off-season periods. The supplier states that products are sold in more than 160 countries and regions and that exports represent 90% of total sales. However, finished-product inspection has instructions but no written records, and the supplier reports no in-stock capacity, overseas warehouse, overseas showroom, or offline trade-show participation. Certification information is limited to “Others” for management systems and CE for product certification. Financial records are identified for 2020–2022, but the provided slices do not establish financial strength.

Supplier typeThe supplier presents itself as a manufacturer with medical consumables production bases and one-stop production from raw materials to finished products. It also provides OEM services for well-known brands and ODM services, indicating a manufacturer and design-manufacturing supplier profile.

After-Sales capabilityThe supplier has documented procedures and records for corrective and preventive actions and customer complaints, and offers training through overseas agents or branches. Nevertheless, it reports no overseas warehouse, overseas showroom, or in-stock service capacity, so the overall after-sales infrastructure is only partially demonstrated.

R&D capabilityThe supplier reports new products within the past year, ODM capability, and an available SDK. It also reports two years of total R&D-engineer experience, but the available information does not establish the scale or depth of its innovation resources.

Production capacityThe supplier operates one production line, has valid manufacturing contracts with each associated subcontractor, and reports lead times within 15 workdays in both peak and off-season. It lacks in-stock capacity, while finished-product inspection has instructions but no written records, indicating operational capability with a documented inspection weakness.

Customization capabilityThe supplier explicitly offers customization from samples and provides both OEM and ODM services. Its available SDK further supports product-related customization, although no broader customization scope is specified.

Client casesThe supplier reports OEM service for well-known brands, sales in more than 160 countries and regions, and customer segments including hospitals, pharmacies, medical-device wholesalers, independent brand owners, and governments. The slices do not identify customer names or provide verifiable case details, but they do show broad claimed market exposure.